Immunovant reports narrower loss and positive rheumatoid arthritis trial data
+2 new sources since this summary was written
On November 9, 2026, Immunovant reported a quarterly net loss of $97.2 million, compared with $126.5 million in the year-earlier period, and cash and cash equivalents of $722.3 million at September 30, 2026. Its IMVT-1402 600 mg dose met the primary endpoint in difficult-to-treat rheumatoid arthritis, with a Week 28 ACR20 response rate of 92.5% versus 75.6% for placebo. The company said it plans to discuss the program with the FDA later this year.
Why it matters
The rheumatoid arthritis result gives IMVT-1402 a stated regulatory next step, with FDA discussions planned later this year. Immunovant also said it is unlikely to advance the drug beyond its ongoing Phase 2 trial in Sjögren’s disease, concentrating development attention on other indications.
Key facts
- 1Quarterly research and development spending was $85.0 million, down from $114.2 million in the prior-year period. tradingview.com
- 2The 300 mg rheumatoid arthritis group recorded a 75.0% response rate and did not differ from placebo. tradingview.com
- 3Immunovant reported no serious adverse events, Grade 3 or higher treatment-emergent adverse events, or treatment discontinuations in any trial arm during Period 2. tradingview.com
- 4The company expects topline results from potentially registrational trials in Graves’ disease and myasthenia gravis in 2027, and in chronic inflammatory demyelinating polyneuropathy in 2028. tradingview.com
Open questions
- - report GAAP EPS of -$0.47 for the period, while reports a loss of $0.41 per share for the same September 30, 2026 quarter.
- label the reporting period as Q2, while identify it as Q3.
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.